Postprogression treatment of lenvatinib plus PD-1 inhibitor in advanced hepatocellular carcinoma refractory to hepatic arterial infusion chemotherapy.

An, Chao; Fu, Yan; Li, Wang; Zuo, Mengxuan; Wu, Peihong

An, Chao; Fu, Yan; Li, Wang; Zuo, Mengxuan; Wu, Peihong.

Afiliación

An C; Department of Minimal Invasive Intervention, Sun Yat-sen University Cancer Center, Guangzhou, China.
Fu Y; State Key Laboratory of Oncology in South China, Guangzhou, China.
Li W; Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.
Zuo M; Department of Interventional Therapy, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Wu P; Department of Minimal Invasive Intervention, Sun Yat-sen University Cancer Center, Guangzhou, China.

Cancer ; 129(14): 2235-2244, 2023 07 15.

Article en En | MEDLINE | ID: mdl-37029486

Asunto(s)

Antineoplásicos; Carcinoma Hepatocelular; Neoplasias Hepáticas; Humanos; Carcinoma Hepatocelular/patología; Antineoplásicos/efectos adversos; Inhibidores de Puntos de Control Inmunológico/uso terapéutico; Sorafenib; Neoplasias Hepáticas/patología; Resultado del Tratamiento; Infusiones Intraarteriales; Protocolos de Quimioterapia Combinada Antineoplásica/efectos adversos

Palabras clave

PD-1; advanced hepatocellular carcinoma; hepatic arterial infusion chemotherapy; lenvatinib; progression

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Carcinoma Hepatocelular / Neoplasias Hepáticas / Antineoplásicos Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: Cancer Año: 2023 Tipo del documento: Article País de afiliación: China

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google